Characteristics of 18F-FDG PET/CT in detecting recurrent lesions in patients with squamous cell cervical carcinoma after curative treatment
Main Article Content
Abstract
This study aimed to describe the imaging characteristics and evaluate the diagnostic performance of 18F-FDG PET/CT in detecting suspected recurrent lesions in patients with cervical squamous cell carcinoma after definitive treatment. A descriptive study combining both prospective and retrospective approaches was conducted on 67 patients with clinical and/or paraclinical suspicion of recurrence who underwent 18F-FDG PET/CT at K Hospital. A total of 85 suspected recurrent lesions were identified, of which 41 were confirmed by histopathology, while the remaining lesions were verified through clinical follow-up, imaging findings, and tumor marker (SCC-Ag) monitoring for at least six months. The diagnostic performance of 18F-FDG PET/CT showed a sensitivity of 96.43%, specificity of 77.78%, and overall accuracy of 93.14% for detecting recurrence. The area under the ROC curve (AUC) was 0.87. The positive likelihood ratio (LR+) was 4.34 (95% CI: 1.85 – 10.13) and the negative likelihood ratio (LR−) was 0.05 (95% CI: 0.02 – 0.14). These findings indicate that 18F-FDG PET/CT is an effective imaging modality for detecting recurrence in patients with cervical cancer after definitive treatment and may assist in guiding subsequent management and follow-up.
Article Details
Keywords
18F-FDG PET/CT, cervical cancer, squamous cell carcinoma, recurrence
References
2. Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2006;95 Suppl 1:S43-103. doi:10.1016/S0020-7292(06)60030-1
3. Backer-Meurke S, Agyemang A, Castellano T, et al. Management of Recurrent and Metastatic Cervical Cancer: A Review of Current Practice. Oncol AMJ Oncol 21 2025. 2025;2(1):126-138. doi:10.33590/oncolamj/XRET2117
4. Yadav D, O’Dwyer E, Agee M, et al. Unraveling the Role of PET in Cervical Cancer: Review of Current Applications and Future Horizons. J Imaging. 2025;11(2):63. doi:10.3390/jimaging11020063
5. Sookha RR, Zhi W, Shen Y, et al. Clinical Value of Combining 18F-FDG PET/CT and Routine Serum Tumor Markers in The Early Detection of Recurrence Among Follow-up Patients Treated for Cervical Squamous Cell Carcinoma. J Cancer. 2018;9(17):3101-3108. doi:10.7150/jca.27206
6. Hellwig D, Graeter TP, Ukena D, et al. 18F-FDG PET for Mediastinal Staging of Lung Cancer: Which SUV Threshold Makes Sense? J Nucl Med. 2007;48(11):1761-1766. doi:10.2967/jnumed.107.044362
7. Choi J, Kim HJ, Jeong YH, et al. The Role of 18 F-FDG PET/CT in Assessing Therapy Response in Cervix Cancer after Concurrent Chemoradiation Therapy. Nucl Med Mol Imaging. 2014;48(2):130-136. doi:10.1007/s13139-013-0248-y
8. Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging. 2008;8(1):146-155. doi:10.1102/1470-7330.2008.0022
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. Published online Version 2025. Accessed March 25, 2026. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf
10. Mittra E, El-Maghraby T, Rodriguez CA, et al. Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(12):1952-1959. doi:10.1007/s00259-009-1206-x
11. Burger IA, Vargas HA, Donati OF, et al. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecol Oncol. 2013;129(3):586-592. doi:10.1016/j.ygyno.2013.01.017
12. Ding X ping, Feng L, Ma L. Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis. Arch Gynecol Obstet. 2014;290(4):741-747. doi:10.1007/s00404-014-3263-z
13. Stojiljkovic M, Sobic Saranovic D, Odalovic S, et al. FDG PET-CT As an Important Diagnostic Tool and Prognostic Marker in Suspected Recurrent Cervical Carcinoma After Radiotherapy: Comparison with MRI. Radiol Oncol. 2022;56(4):453-460. doi:10.2478/raon-2022-0042